A biotech company co-founded by venture capital firm Atlas Venture has shut down after running into problems with its lead drug and raising new funding.
Triplet Therapeutics, which was based in Cambridge, Mass., launched in 2019 with a $59 million Series A round from a group of VCs including Atlas, MPM Capital, and Pfizer Ventures.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
